318 related articles for article (PubMed ID: 36681073)
1. A critical review of upadacitinib for the treatment of adults with moderately to severely active ulcerative colitis.
Law CCY; Kayal M; Mehandru S; Colombel JF
Expert Rev Gastroenterol Hepatol; 2023 Feb; 17(2):109-117. PubMed ID: 36681073
[TBL] [Abstract][Full Text] [Related]
2. Efficacy of Upadacitinib in a Randomized Trial of Patients With Active Ulcerative Colitis.
Sandborn WJ; Ghosh S; Panes J; Schreiber S; D'Haens G; Tanida S; Siffledeen J; Enejosa J; Zhou W; Othman AA; Huang B; Higgins PDR
Gastroenterology; 2020 Jun; 158(8):2139-2149.e14. PubMed ID: 32092309
[TBL] [Abstract][Full Text] [Related]
3. Evaluating Upadacitinib in the Treatment of Moderate-to-Severe Active Ulcerative Colitis: Design, Development, and Potential Position in Therapy.
Napolitano M; D'Amico F; Ragaini E; Peyrin-Biroulet L; Danese S
Drug Des Devel Ther; 2022; 16():1897-1913. PubMed ID: 35747444
[TBL] [Abstract][Full Text] [Related]
4. Pharmacokinetics of Upadacitinib in Healthy Subjects and Subjects With Rheumatoid Arthritis, Crohn's Disease, Ulcerative Colitis, or Atopic Dermatitis: Population Analyses of Phase 1 and 2 Clinical Trials.
Nader A; Stodtmann S; Friedel A; Mohamed MF; Othman AA
J Clin Pharmacol; 2020 Apr; 60(4):528-539. PubMed ID: 31701537
[TBL] [Abstract][Full Text] [Related]
5. A review of upadacitinib in rheumatoid arthritis.
Tanaka Y
Mod Rheumatol; 2020 Sep; 30(5):779-787. PubMed ID: 32530345
[TBL] [Abstract][Full Text] [Related]
6. Safety and efficacy of upadacitinib in patients with active rheumatoid arthritis refractory to biologic disease-modifying anti-rheumatic drugs (SELECT-BEYOND): a double-blind, randomised controlled phase 3 trial.
Genovese MC; Fleischmann R; Combe B; Hall S; Rubbert-Roth A; Zhang Y; Zhou Y; Mohamed MF; Meerwein S; Pangan AL
Lancet; 2018 Jun; 391(10139):2513-2524. PubMed ID: 29908670
[TBL] [Abstract][Full Text] [Related]
7. Safety of Upadacitinib in Immune-Mediated Inflammatory Diseases: Systematic Literature Review of Indirect and Direct Treatment Comparisons of Randomized Controlled Trials.
Mysler E; Burmester GR; Saffore CD; Liu J; Wegrzyn L; Yang C; Betts KA; Wang Y; Irvine AD; Panaccione R
Adv Ther; 2024 Feb; 41(2):567-597. PubMed ID: 38169057
[TBL] [Abstract][Full Text] [Related]
8. Upadacitinib Population Pharmacokinetics and Exposure-Response Relationships in Ulcerative Colitis Patients.
Ponce-Bobadilla AV; Stodtmann S; Eckert D; Zhou W; Liu W; Mohamed MF
Clin Pharmacokinet; 2023 Jan; 62(1):101-112. PubMed ID: 36571701
[TBL] [Abstract][Full Text] [Related]
9. Upadacitinib: Mechanism of action, clinical, and translational science.
Mohamed MF; Bhatnagar S; Parmentier JM; Nakasato P; Wung P
Clin Transl Sci; 2024 Jan; 17(1):e13688. PubMed ID: 37984057
[TBL] [Abstract][Full Text] [Related]
10. Upadacitinib as induction and maintenance therapy for moderately to severely active ulcerative colitis: results from three phase 3, multicentre, double-blind, randomised trials.
Danese S; Vermeire S; Zhou W; Pangan AL; Siffledeen J; Greenbloom S; Hébuterne X; D'Haens G; Nakase H; Panés J; Higgins PDR; Juillerat P; Lindsay JO; Loftus EV; Sandborn WJ; Reinisch W; Chen MH; Sanchez Gonzalez Y; Huang B; Xie W; Liu J; Weinreich MA; Panaccione R
Lancet; 2022 Jun; 399(10341):2113-2128. PubMed ID: 35644166
[TBL] [Abstract][Full Text] [Related]
11. Upadacitinib as monotherapy in patients with active rheumatoid arthritis and inadequate response to methotrexate (SELECT-MONOTHERAPY): a randomised, placebo-controlled, double-blind phase 3 study.
Smolen JS; Pangan AL; Emery P; Rigby W; Tanaka Y; Vargas JI; Zhang Y; Damjanov N; Friedman A; Othman AA; Camp HS; Cohen S
Lancet; 2019 Jun; 393(10188):2303-2311. PubMed ID: 31130260
[TBL] [Abstract][Full Text] [Related]
12. Safety and efficacy of upadacitinib in patients with rheumatoid arthritis and inadequate response to conventional synthetic disease-modifying anti-rheumatic drugs (SELECT-NEXT): a randomised, double-blind, placebo-controlled phase 3 trial.
Burmester GR; Kremer JM; Van den Bosch F; Kivitz A; Bessette L; Li Y; Zhou Y; Othman AA; Pangan AL; Camp HS
Lancet; 2018 Jun; 391(10139):2503-2512. PubMed ID: 29908669
[TBL] [Abstract][Full Text] [Related]
13. Evaluating upadacitinib for the treatment of rheumatoid arthritis.
Mysler E; Lizarraga A
Expert Opin Pharmacother; 2020 Sep; 21(13):1527-1536. PubMed ID: 32515665
[TBL] [Abstract][Full Text] [Related]
14. Efficacy and safety of upadacitinib for 16-week extended induction and 52-week maintenance therapy in patients with moderately to severely active ulcerative colitis.
Panaccione R; Danese S; Zhou W; Klaff J; Ilo D; Yao X; Levy G; Higgins PDR; Loftus EV; Chen S; Gonzalez YS; Leonard C; Hébuterne X; Lindsay JO; Cao Q; Nakase H; Colombel JF; Vermeire S
Aliment Pharmacol Ther; 2024 Feb; 59(3):393-408. PubMed ID: 38010661
[TBL] [Abstract][Full Text] [Related]
15. Upadacitinib in Rheumatoid Arthritis: A Benefit-Risk Assessment Across a Phase III Program.
Conaghan PG; Mysler E; Tanaka Y; Da Silva-Tillmann B; Shaw T; Liu J; Ferguson R; Enejosa JV; Cohen S; Nash P; Rigby W; Burmester G
Drug Saf; 2021 May; 44(5):515-530. PubMed ID: 33527177
[TBL] [Abstract][Full Text] [Related]
16. Upadacitinib in Crohn's disease.
Dignass A; Esters P; Flauaus C
Expert Opin Pharmacother; 2024 Mar; 25(4):359-370. PubMed ID: 38512115
[TBL] [Abstract][Full Text] [Related]
17. Efficacy and safety of upadacitinib in patients with active ankylosing spondylitis (SELECT-AXIS 1): a multicentre, randomised, double-blind, placebo-controlled, phase 2/3 trial.
van der Heijde D; Song IH; Pangan AL; Deodhar A; van den Bosch F; Maksymowych WP; Kim TH; Kishimoto M; Everding A; Sui Y; Wang X; Chu AD; Sieper J
Lancet; 2019 Dec; 394(10214):2108-2117. PubMed ID: 31732180
[TBL] [Abstract][Full Text] [Related]
18. Filgotinib for moderately to severely active ulcerative colitis.
Mannucci A; D'Amico F; El Saadi A; Peyrin-Biroulet L; Danese S
Expert Rev Gastroenterol Hepatol; 2022 Oct; 16(10):927-940. PubMed ID: 36278878
[TBL] [Abstract][Full Text] [Related]
19. Efficacy and safety of upadacitinib for active ankylosing spondylitis refractory to biological therapy: a double-blind, randomised, placebo-controlled phase 3 trial.
van der Heijde D; Baraliakos X; Sieper J; Deodhar A; Inman RD; Kameda H; Zeng X; Sui Y; Bu X; Pangan AL; Wung P; Song IH
Ann Rheum Dis; 2022 Nov; 81(11):1515-1523. PubMed ID: 35788492
[TBL] [Abstract][Full Text] [Related]
20. Herpes zoster in patients with inflammatory arthritides or ulcerative colitis treated with tofacitinib, baricitinib or upadacitinib: a systematic review of clinical trials and real-world studies.
Gialouri CG; Moustafa S; Thomas K; Hadziyannis E; Vassilopoulos D
Rheumatol Int; 2023 Mar; 43(3):421-435. PubMed ID: 36635577
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
